WO2004004764A1 - Composition contre la morphee en gouttes - Google Patents

Composition contre la morphee en gouttes Download PDF

Info

Publication number
WO2004004764A1
WO2004004764A1 PCT/JP2003/008131 JP0308131W WO2004004764A1 WO 2004004764 A1 WO2004004764 A1 WO 2004004764A1 JP 0308131 W JP0308131 W JP 0308131W WO 2004004764 A1 WO2004004764 A1 WO 2004004764A1
Authority
WO
WIPO (PCT)
Prior art keywords
white spot
virus
spot disease
antibody
envelope
Prior art date
Application number
PCT/JP2003/008131
Other languages
English (en)
Japanese (ja)
Inventor
Yoshikatsu Kodama
Hideaki Yokoyama
Sa Van Nguyen
Original Assignee
Ghen Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ghen Corporation filed Critical Ghen Corporation
Priority to AU2003244102A priority Critical patent/AU2003244102A1/en
Priority to BR0312505-0A priority patent/BR0312505A/pt
Publication of WO2004004764A1 publication Critical patent/WO2004004764A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds

Definitions

  • the present invention relates to a composition which is effective for the prevention and treatment of white spot disease virus (white spot syndrome virus) infection of crustaceans such as shrimp and rikiji, ie, white spot disease.
  • white spot disease virus white spot syndrome virus
  • crustaceans such as shrimp and rikiji, ie, white spot disease.
  • Crustacean white spot disease see Crustacean white spot disease.
  • the present invention relates to a composition which is extremely effective in protecting against infection from the environment, reducing death and loss associated with infection with the virus, or treating the virus.
  • White spot disease is currently untreatable.
  • the main preventive measure for white spot disease is hygiene. If white spot disease virus is detected in a shrimp pond, incinerate all shrimp and disinfect the pond water. However, it is difficult to prevent transmission of the virus due to the large number of carriers of the virus. Also, unlike mammals and various fish, shrimp and other crustaceans have no immune cells, so vaccine development is not possible. Disclosure of the invention
  • White spot disease is an acute viral disease found in various types of shrimp. Rinji and other crustaceans are known to be carriers of the virus. Shrimp are infected at all stages of development, spread very quickly, and often have a mortality rate of 100% within a week. Shrimp and other crustaceans cannot produce antibodies to the virus because they lack immune cells. Therefore, by providing an exogenous specific antibody, the pathogenic virus can be neutralized outside and inside the body, and infection can be prevented.
  • the present inventors have conducted intensive studies to solve the above-mentioned problems and found that All virions and envelopes of white spot syndrome virus, and chicken eggs obtained by immunizing chickens with at least one selected from the constituent proteins of the envelope and immunogenic fragments thereof.
  • the present inventors have found that administration of an antibody to shrimp or other crustaceans can neutralize the virus and eliminate its pathogenicity, thereby completing the present invention.
  • the present invention includes the following inventions.
  • An anti-white spot syndrome composition comprising an antibody obtained from an egg.
  • composition according to the above (1) which is used for prevention or treatment of white spot disease.
  • a method for preventing or treating white spot disease which comprises administering the antibody according to (1) to a crustacean.
  • the antigen at least one selected from all virions and envelopes of the shrimp white spot virus, and the constituent proteins of the envelope and immunogenic fragments thereof is used.
  • the white spot disease virus used as an antigen is not particularly limited as long as it is an available virus strain, and examples thereof include the WSSV strain described in J. Virol. 75: 11811-11820 (2001). In addition, these viruses can be used in the form of shrimp cells or shrimp and other crustaceans.
  • the envelope of the present virus can be obtained, for example, by the method described in Virol. 266: 227-236 (2000) in which fractionation is performed by ultracentrifugation after Nonidet-P40 treatment.
  • the protein constituting the envelope include a 28 kD protein (VP 28) described in Virol. 285: 228-233 (2001), and a protein described in J. Gen. Virol. 83: 257-265 (2002).
  • the 19 kD protein (VP19) can be used.
  • the immunogenic fragment comprises one or more epitopes, There is no particular limitation as long as it can be used as.
  • a peptide having 3 or more amino acid residues can be considered, preferably 5 or more amino acid residues, more preferably 10 or more amino acid residues, or a protein constituting the envelope or an immunogen thereof.
  • Functional fragments can be synthesized by peptide synthesis methods such as the liquid phase method and the solid phase method. Further, an automatic peptide synthesizer may be used.
  • constituent proteins of the envelope or the immunogenic fragments thereof may be obtained from DNA or RNA having a corresponding nucleotide sequence by genetic engineering techniques (for example, “Sequence Chemistry Experimental Course 1 Genetic Research Method I” edited by The Biochemical Society of Japan, Tokyo Kagaku Dojin, 1996, Ed., The Biochemical Society of Japan, edited by The Biochemical Chemistry Lecture 1, Gene Research Method II, Tokyo Kagaku Dojin, 1996, Japan Biochemical Society, Ed. Method III ”, Tokyo Kagaku Dojin, 1987).
  • the immunogenic fragment is a low molecular substance
  • a fragment obtained by binding a carrier to the fragment is usually used.
  • the carrier include keyhole limpet hemocyanin (KLH), sea urchin serum albumin (BSA), human serum albumin (HSA), chicken serum albumin, poly-L-lysine, polyalanyl lysine, dipalmityl lysine, Tetanus toxoid or polysaccharide can be used.
  • Glutaraldehyde method 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide method, maleimidobenzoyl-N-hydroxysuccinimide ester method, bisdiazobenzidine
  • a known method such as the N-succimidyl-13- (2-pyridyldithio) propionic acid method can be used.
  • the immunogen can be obtained by adsorbing the immunogenic fragment to a carrier such as nitrocellulose particles, polyvinylpyrrolidone, and ribosome.
  • the chicken used for the preparation of the antibody is not limited, as long as it is a laying hen.
  • Examples of the immunization method include subcutaneous injection, intramuscular injection, and oral administration of an immunogen (the protein constituting the envelope or an immunogenic fragment thereof). Inoculated immunogenic amount of 1 0 3 ⁇ 1 0 9 TC ID 5. (TCID 5Q : 50% infectious dose of cultured cells), or 0.05 to 2 mg as various proteins or peptides derived from this virus.
  • a higher antibody titer can be obtained by boosting 3 to 10 weeks after the initial immunization. Two weeks after the booster, antibodies specifically reacting to the white spot virus are produced not only in chicken serum but also in egg yolk. Chicken immunized in this way usually maintains a high antibody titer for about 3 months.
  • the antibody activity in the serum and egg yolk is measured by a fluorescent antibody method, ELISA or virus neutralization reaction, and expressed as an antibody titer.
  • the immunogen is preferably mixed with an adjuvant and injected by immunization.
  • adjuvant known adjuvants such as Freund's complete adjuvant, Freund's incomplete adjuvant, aluminum hydroxide adjuvant, and B. pertussis adjuvant can be used.
  • the antibody of the egg obtained as described above can be used as a solution as whole egg or yolk, or dried and powdered with a spray dryer or the like, or defatted from whole egg or yolk and used as an egg.
  • a water-soluble protein may be used, and the antibody may be further purified or roughly purified.
  • composition of the invention is applied to crustaceans, especially shrimp.
  • the dose of the antibody is generally 0.01% to 10% of the diet, but is preferably adjusted appropriately according to the type of crustacean, the stage of development, the degree of virus infection, and the like.
  • the anti-white spot disease composition of the present invention comprises a solution having a concentration of each active ingredient of 0.001% to 10%, and further has a powder, granule, tablet, or paste form in which the concentration of each active ingredient in the feed is increased.
  • the salary ranges from 0.001% to 10%.
  • FIG. 1 shows the test results of Example 4.
  • FIG. 2 shows the test results of Example 5.
  • This description includes part or all of the contents as disclosed in the description and Z or drawings of Japanese Patent Application No. 2002-199033, which is a priority document of the present application.
  • the purified white spot disease virus was treated with Nonidet-P40 and centrifuged. The envelope remaining in the soluble fraction was recovered from the viral virion. A 12-week-old hen was immunized using 0.1 mg of this envelope as an antigen. Similarly, a second immunization was performed 6 weeks later. Two weeks after the second immunization, the neutralizing antibody titer of the anti-White spot disease virus antibody in the serum of this chicken was 16000-fold. The eggs laid by the chicken had a neutralizing antibody titer of 16,000-fold. This antibody titer lasted for about 3 months.
  • the 28 kD protein of the white spot virus envelope (VP 28) (Virol. 285: 228-233 (2001)) was purified from the envelope and used as a chicken immunogen. Was 8000 times. Also, the envelope 19 kD protein (VP 19) (J. Gen. Virol. 83: 257-265 (2002)) When produced and immunized by the method, the obtained titer of neutralizing antibody for chicken eggs was 8000-fold. (Example 4)
  • Black tiger (Penaeus monodon) shrimp (1 g body weight), 1% by weight of whole egg powder (neutralizing antibody titer: 12,000 units Zg) containing anti-white spot disease virus antibody was added to the diet for 40 days. Bred.
  • White spot disease virus 10 9 TC ID 5 was experimentally infected in each shrimp tank, and no abnormalities were observed in the treatment group. However, in the control shrimp group that did not receive the anti-white spot disease virus antibody powder, the disease began to develop on day 10 after virus infection and died 100% on day 32 (Fig. 1).
  • the anti-white spot disease composition of the present invention acts specifically on the white spot disease virus, it exhibits an extremely effective preventive effect against white spot disease of epipis and other crustaceans. It is extremely effective in stopping the transmission of this disease in shrimp populations previously infected with the virus.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Birds (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Insects & Arthropods (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Feed For Specific Animals (AREA)
  • Fodder In General (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne une composition contre la morphée en gouttes renfermant un anticorps obtenu à partir d'un oeuf d'une poule ayant été immunisée au moyen d'au moins un élément sélectionné parmi l'ensemble du virion du virus de morphée en gouttes de crevettes, l'enveloppe de celui-ci, une protéine constituant l'enveloppe et un fragment immunogénique de celle-ci ; ainsi qu'une méthode de prévention ou de traitement de la morphée en gouttes consistant à administrer l'anticorps susmentionné à des crustacés.
PCT/JP2003/008131 2002-07-08 2003-06-26 Composition contre la morphee en gouttes WO2004004764A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003244102A AU2003244102A1 (en) 2002-07-08 2003-06-26 Composition against white spot disease
BR0312505-0A BR0312505A (pt) 2002-07-08 2003-06-26 Composição anti-sìndrome da mancha branca

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002-199033 2002-07-08
JP2002199033A JP2004041005A (ja) 2002-07-08 2002-07-08 抗ホワイトスポット病組成物

Publications (1)

Publication Number Publication Date
WO2004004764A1 true WO2004004764A1 (fr) 2004-01-15

Family

ID=30112445

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/008131 WO2004004764A1 (fr) 2002-07-08 2003-06-26 Composition contre la morphee en gouttes

Country Status (5)

Country Link
JP (1) JP2004041005A (fr)
AU (1) AU2003244102A1 (fr)
BR (1) BR0312505A (fr)
TW (1) TW200404566A (fr)
WO (1) WO2004004764A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100443502C (zh) * 2004-06-05 2008-12-17 大连理工大学 一种防治对虾病毒病的卵黄免疫球蛋白及其制备方法和应用
CN106942521A (zh) * 2017-02-28 2017-07-14 中国海洋大学 一种药性稳定的用于对虾免疫增强和杀菌的中草药制剂及方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007084495A (ja) * 2005-09-22 2007-04-05 Daikin Ind Ltd ウイルス感染細胞処理方法
JP2012158562A (ja) * 2011-02-02 2012-08-23 Kyoorin:Kk 鯉の新型穴あき病の予防方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05255113A (ja) * 1992-03-16 1993-10-05 Taiyo Kagaku Co Ltd 特異的抗体及びそれを配合してなるエビ類感染症防除組成物
JPH08131087A (ja) * 1994-11-11 1996-05-28 Taiyo Kagaku Co Ltd 餌料用組成物
JPH11279198A (ja) * 1998-03-31 1999-10-12 Natl Res Inst Of Aquaculture Ｐｒｄｖに対する抗体
WO2002022664A2 (fr) * 2000-09-15 2002-03-21 Akzo Nobel N.V. Proteines antigeniques du virus de la maladie du point blanc (wssv) de la crevette et utilisations de ces proteines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05255113A (ja) * 1992-03-16 1993-10-05 Taiyo Kagaku Co Ltd 特異的抗体及びそれを配合してなるエビ類感染症防除組成物
JPH08131087A (ja) * 1994-11-11 1996-05-28 Taiyo Kagaku Co Ltd 餌料用組成物
JPH11279198A (ja) * 1998-03-31 1999-10-12 Natl Res Inst Of Aquaculture Ｐｒｄｖに対する抗体
WO2002022664A2 (fr) * 2000-09-15 2002-03-21 Akzo Nobel N.V. Proteines antigeniques du virus de la maladie du point blanc (wssv) de la crevette et utilisations de ces proteines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TANAKA M. ET AL.: "Production of the monoclonal antibodies against white spot syndrome virus in penaeid shrimp", 70TH ANNIVERSARY OF THE JAPANESE SOCIETY OF FISHERIES SCIENCE INTERNATIONAL COMMEMORATIVE SYMPOSIUM PROGRAM & ABSTRACTS, 2001, pages 235, XP002971871 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100443502C (zh) * 2004-06-05 2008-12-17 大连理工大学 一种防治对虾病毒病的卵黄免疫球蛋白及其制备方法和应用
CN106942521A (zh) * 2017-02-28 2017-07-14 中国海洋大学 一种药性稳定的用于对虾免疫增强和杀菌的中草药制剂及方法

Also Published As

Publication number Publication date
TW200404566A (en) 2004-04-01
AU2003244102A1 (en) 2004-01-23
JP2004041005A (ja) 2004-02-12
BR0312505A (pt) 2005-04-12

Similar Documents

Publication Publication Date Title
JP4362049B2 (ja) Ｄｎａ転写ユニットの接種による免疫化
GB2253626A (en) Antigen-presenting chimaeric protein
SK362692A3 (en) Expression of specific immunogens by using of virus antigene
HU230364B1 (hu) Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására
RU2008102930A (ru) Способы введения вакцин, новые калицивирусы кошки и варианты лечения для иммунизации животных против парвовируса кошки и вируса герпеса кошки
SK287382B6 (sk) Očkovacia kompozícia
EA006308B1 (ru) Пептиды вич, антигены, вакцинные композиции, набор для иммуноанализа и способ обнаружения антител, индуцируемых вич
JPH06502539A (ja) Ｈｉｖ−１　ｇｐ１２０のｖ３ループおよびｃｄ−４結合部位に特異的な中和ヒトモノクローナル抗体
PT1523329E (pt) Partícula viral adjuvante
Frangione-Beebe et al. Enhanced immunogenicity of a conformational epitope of human T-lymphotropic virus type 1 using a novel chimeric peptide
WO2004002527A1 (fr) Compositions dirigees contre la coccidiose du poulet
JPH02500519A (ja) 免疫療法の方法及び組成物
MXPA03006819A (es) Metodos y composiciones para eltratamiento de transtornos de disfuncion inmune.
Karpenko et al. Combined virus-like particle-based polyepitope DNA/protein HIV-1 vaccine: Design, immunogenicity and toxicity studies
MXPA03006818A (es) Metodos y composiciones para modular el sistema inmune de animales.
RU2358981C2 (ru) Универсальная вакцина против вируса гриппа птиц
WO2004004764A1 (fr) Composition contre la morphee en gouttes
JP4724000B2 (ja) ポリペプチド
WO2003070258A1 (fr) Anticorps igy dirige contre le virus de la maladie des points blancs
EP0783038A1 (fr) Pseudo-particules virales recombinantes et applications vaccinales et antitumorales
JPWO2009001673A1 (ja) Ａｔｐ含有免疫アジュバント
JP2010029217A (ja) Ｈｉｖ特異的ｃｔｌを誘導し得るペプチド及び該ペプチドを含む抗ａｉｄｓ予防・治療剤
EP1578791B1 (fr) Corps d'inclusion pour la vaccination orale d'animaux
JP5047431B2 (ja) 炎症を低減させるグルコサミンおよび卵
JP2002518033A (ja) 農場動物の成長促進のための合成ソマトスタチン免疫原

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 20038160668

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 114/MUMNP/2005

Country of ref document: IN

122 Ep: pct application non-entry in european phase